register

News & Trends - MedTech & Diagnostics

First bedside point-of-care test approved for COVID-19 virus

Health Industry Hub | March 23, 2020 |

MedTech News: Cepheid point-of-care diagnostic test is the first to receive Emergency Use Authorisation from the U.S. Food & Drug Administration (FDA) for qualitative detection of SARS-CoV.

The test is designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert Systems worldwide, with a detection time of approximately 45 minutes.

Although the TGA is providing exemptions for the immediate supply of COVID-19 tests, the prospect of introducing this approach of identifying asymptomatic people and isolating them is not currently practical on a large scale. There are not enough tests to go around. COVID-19 testing is really targeted for high-risk patients and patients who show signs and symptoms of the disease. Broad based testing at this stage is simply not feasible.

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“During this time of increased demand for hospital services, clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities. An accurate test delivered close to the patient can be transformative and help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on healthcare facilities that need to properly allocate their respiratory isolation resources,” said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid.

“By leveraging the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and potential future variants of SARS-CoV-2, we have developed a test that provides reference lab-quality results in multiple settings where actionable treatment information is needed quickly.”

“Our automated systems do not require users to have specialty training to perform testing — they are capable of running 24/7, with many systems already doing so today.” said Cepheid President Warren Kocmond.

The test will begin shipping next week in the U.S. and is pending review by international regulatory agencies, including Australia’s TGA.

Customer engagement during COVID-19 – solutions developed by industry for industry. Learn more about how we can help your team. We combine our expertise in delivering and measuring the engagement from digital health content, with 20+ years industry experience.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.